|
|
|
|
|
|
|
|
|
|
|
|
|
10.08.26 - 15:06
|
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman (Business Wire)
|
|
|
Dr. Kim will advise on international partnerships and global access initiatives through the newly formed Office of the Executive ChairmanCULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and global relationships. He will report to Executive Chairman and Founder Dr. Patrick Soon-Shiong.
The Office of the Executive Chairman will bring together senior leaders to support Dr. Soon-Shiong on strategy, partnerships, and initiatives intended to advance ImmunityBio's scientific and clinical programs globally. In his role, Dr. Kim will focus on relationships with governments, health ministries, multilateral institutions, and global health partners, with the goal of supporting access to the company's immunotherapy platform, clinical progr...
|
|
|
|
|
|
|
04.08.26 - 13:36
|
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million (Business Wire)
|
|
|
Q2 2026 net product revenue of $50.7 million, up 92% year-over-year and 15% sequentially from Q1 2026, marking the eighth consecutive quarter of sequential revenue growth since the commercial launch of ANKTIVA®, driven by continued adoption among U.S. urologists and strong market access
First-half 2026 net product revenue of $94.8 million, up 121% compared with the first-half of 2025
In July 2026, we announced the Emirates Drug Establishment of the United Arab Emirates granted the broadest marketing authorization for ANKTIVA across BCG-unresponsive NMIBC for CIS and papillary disease and metastatic NSCLC
The FDA accepted for review the Company's supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG in patients with BCG-unresponsive NMIBC with papillary disease without CIS and assigned a PDUFA target action date of January 6, 2027
Continued advancement across the clinical pipeline, with multiple anticipated regulatory, clinical, and data milestones expected over the next 12 months, inclu...
|
|
|
|
|
10.07.26 - 18:06
|
Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout (24/7 Wall St.)
|
|
|
Biotech is the story at midday Friday, and it's not a pretty one for shareholders who chased the sector's monster 2026 run. Moderna (NASDAQ:MRNA) stock is down 11% to $68.50, ImmunityBio (NASDAQ:IBRX) shares are off 8% to $8.16, and Sarepta Therapeutics (NASDAQ:SRPT) stock has slid 8% to $18.84. The moves are steep, but they land ... Moderna Drops 11%, ImmunityBio and Sarepta Therapeutics Tumble 8% in Biotech Rout...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
